The multidrug resistance protein 5 (ABCC5) confers resistance to 5-fluorouracil and transports its monophosphorylated metabolites

Molecular Cancer Therapeutics

Volumn 4, Issue 5, 2005, Pages 855-863

  Pratt, Susan ^a   Shepard, Robert L ^a   Kandasamy, Ramani A ^b   Johnston, Paul A ^b   Perry III, William ^a   Dantzig, Anne H ^a  

^a ELI LILLY AND COMPANY   (United States)

^b RTP Laboratories   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

5 NITRO 2 (3 PHENYLPROPYLAMINO)BENZOIC ACID; ADENOSINE TRIPHOSPHATE; CHLORIDE CHANNEL BLOCKING AGENT; CISPLATIN; CYCLIC GMP; CYCLIC NUCLEOTIDE; DOXORUBICIN; DRUG METABOLITE; FLUOROURACIL; GLIBENCLAMIDE; METHOTREXATE; MULTIDRUG RESISTANCE PROTEIN 5; OXALIPLATIN; PEMETREXED; PHOSPHODIESTERASE INHIBITOR; PROBENECID; SILDENAFIL; TIOGUANINE; TREQUINSIN; VERLUKAST; VINCRISTINE; ZAPRINAST;

ARTICLE; BREAST CANCER; CANCER RESISTANCE; COLON CANCER; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOTOXICITY; DRUG ACCUMULATION; DRUG SENSITIVITY; DRUG TRANSPORT; DRUG UPTAKE; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; INHIBITION KINETICS; KIDNEY CELL; MEMBRANE VESICLE; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL;

ADENOSINE TRIPHOSPHATE; ANTIMETABOLITES, ANTINEOPLASTIC; APOPTOSIS; BIOLOGICAL TRANSPORT; CELLS, CULTURED; DRUG RESISTANCE, MULTIPLE; DRUG RESISTANCE, NEOPLASM; FLOXURIDINE; FLUOROURACIL; HUMANS; KIDNEY; MULTIDRUG RESISTANCE-ASSOCIATED PROTEINS; PHOSPHORYLATION; THIOGUANINE; THYMIDYLATE SYNTHASE;

EID: 20044383925     PISSN: 15357163     EISSN: None     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-04-0291     Document Type: Article

References (51)

1. Chu E, Callender MA, Farrell MP, Schmitz JC. Thymidylate synthase inhibitors as anticancer agents: from bench to bedside. Cancer Chemother Pharmacol 2003;52:S80-9.
2. Peters G, Backus H, Freemantle S, et al. Induction of thymidylate synthase as a 5-fluorouracil resistance mechanism. Biochim Biophys Acta 2002;1587:194-205.
3. Santi DV, McHenry CS, Sommer H. Mechanism of interaction of thymidylate synthetase with 5-fluorodeoxyridylate. Biochemistry 1974; 13:471-81.
4. Denenberg P, Denenberg KD. Effect of 5,10-methylenetetrahydrofolate and the dissociation of 5-fluoro-2′-deoxyuridylate from thymidylate synthetase: evidence for an ordered mechanism. Biochemistry 1978;17: 4018-24.
5. Myers CE, Young RC, Chabner BA. Biochemical determinants of 5-fluorouracil response in vivo. The role of deoxyuridylate pool expansion. J Clin Invest 1975;56:1271-8.
6. Peters G, van der Wilt C, van Groeningen C, et al. Thymidylate synthase inhibition after administration of fluorouracil with or without leucovorin in colon cancer patients: implications for treatment with fluorouracil. J Clin Oncol 1994;12:2035-42.
7. Klubes P, Connelly K, Cerna I, Mandel HG. Effects of 5-fluorouracil on 5-fluorodeoxyuridine 5′-monophosphate and 2-deoxyuridine 5′-monophosphate pools, and DNA synthesis in solid mouse L1210 and rat Walker 256 tumors. Cancer Res 1978;38:2325-31.
8. Ardalan B, Buscaglia M, Schein P. Tumor 5-fluorodeoxyuridylate concentration as a determinant of 5-fluorouracil response. Biochem Pharmacol 1978;27:2009-13.
9. Ling V. P-glycoprotein and resistance to anticancer drugs. Cancer 1992; 69:2603 -9.
10. Leonard G, Fojo T, Bates S. The role of ABC transporters in clinical practice. Oncologist 2003;8:411-24.
11. Kruh G, Belinsky M. The MRP family of drug efflux pumps. Oncogene 2003;22:7537-52.
12. Borst P, Elferink R. Mammalian ABC transporters in health and disease. Annu Rev Biochem 2002;71:537-92.
13. Guo Y, Kotova E, Chen Z, et al. MRPB, ATP-binding cassette C11 (ABCC11), is a cyclic nucleotide efflux pump and a resistance factor for fluoropyrimidines 2′,3′-dideoxycytidine and 9′-(2′-phosphonylmethoxyethyl) adenine. J Biol Chem 2003;278:29509-14.
14. Kruh G, Zeng H, Rea P, et al. MRP subfamily transporters and resistance to anticancer agents. J Bioenerg Biomembr 2001;33:493-501.
15. Adachi M, Reid G, Schuetz J. Therapeutic and biological importance of getting nucleotides out of cells: a case for the ABC transporters, MRP4 and 5. Adv Drug Deliv Rev 2002;54:1333-42.
16. Sampath J, Adachi M, Hatse S, et al. Role of MRP4 and MRP5 in biology and chemotherapy. AAPS PharmSci 2002;4:E14.
17. Wijnholds J, Mol CAAM, van Deemter L, et al. Multidrug-resistance protein 5 is a multispecific organic anion transporter able to transport nucleotide analogs. Proc Natl Acad Sci U S A 2000;97:7476-81.
18. Reddy MM, Quinton PM. Effect of anion transport blockers on CFTR in the human sweat duct. J Membr Biol 2002;189:15-25.
19. Godinot N, Iversen P, Tabas L, et al. Cloning and functional characterization of the multidrug resistance associated protein (MRP1/ABCC1) from the Cynomolgus monkey. Mol Cancer Ther 2003;2:307-16.
20. Shepard RL, Cao J, Starling JJ, Dantzig AH. Effect of P-glycoprotein inhibitor, LY335979 on P-glycoprotein, MRP1 and BCRP-mediated resistance. Int J Cancer 2003;103:121-5.
21. Tabas LB, Dantzig AH. A high throughput assay for measurement of multidrug resistance protein (MRP1)-mediated transport of leukotriene C4 into membrane vesicles. Anal Biochem 2002;310:61-6.
22. Shimma N, Umeda I, Arasaki M, et al. The design and synthesis of a new tumor-selective fluoropyrimidine, carbamate, capecitabine. Bioorg Med Chem 2000;8:1697-706.
23. McAleer MA, Breen MA, White NL, Matthews N. pABC11 (also known as MOAT-C and MRP5), a member of the ABC family of proteins, has anion transporter activity but does not confer multidrug resistance when overexpressed in human embryonic kidney 293 cells. J Biol Chem 1999;274:23541-8.
24. Davidson JD, Ma L, Iverson PW, et al. Human multidrug resistance protein 5 (MRP5) confers resistance to gemcitabine. In: Proc Am Assoc Cancer Res; 2002 Apr 6-10; San Francisco, CA. Linthicum: Cadmus; 2002.
25. Yoshida M, Suzuki T, Komiya T, et al. Induction of MRP5 and SMRP mRNA by Adriamycin exposure and its overexpression in human lung cancer cells resistant to Adriamycin. Int J Cancer 2001;94:432-7.
26. Oguri T, Isobe T, Suzuki T, et al. Increased expression of the MRP5 gene is associated with exposure to platinum drugs in lung cancer. Int J Cancer 2000;86:95-100.
27. Borst P, Balzarini J, Ono N, et al. The potential impact of drug transporters on nucleoside-analog-based antiviral chemotherapy. Antiviral Res 2004;62:1-7.
28. Jedlitschky G, Burchell B, Keppler D. The multidrug resistance protein 5 functions as an ATP-dependent export pump for cyclic nucleotides. J Biol Chem 2000;275:30069-74.
29. Reid G, Wielinga P, Zelcer N, et al. The human multidrug resistance protein MRP4 functions as a prostaglandin efflux transporter and is inhibited by nonsteroidal antiinflammatory drugs [comment]. Proc Natl Acad Sci U S A 2003;100:9108-10.
30. Chen Z, Lee K, Kruh G. Transport of cyclic nucleotides and estradiol 17-β-D-glucuronide by multidrug resistance protein 4. Resistance to 6-mercaptopurine and 6-thioguanine. J Biol Chem 2001;276:33747-54.
31. Wielinga P, van der Heijden I, Reid G, et al. Characterization of the MRP4- and MRP5-mediated transport of cyclic nucleotides from intact cells. J Biol Chem 2003;278:17664-71.
32. Wielinga P, Reid G, Challa E, et al. Thiopurine metabolism and identification of the thiopurine metabolites transported by MRP4 and MRP5 overexpressed in human embryonic kidney cells. Mol Pharmacol 2002;62:1321-31.
33. Bera T, Lee S, Salvatore G, Lee B, Pastan I. MRP8, a new member of ABC transporter superfamily, identified by EST database mining and gene prediction program, is highly expressed in breast cancer. Mol Med 2001;7: 509-16.
34. Yabuuchi H, Shimizu H, Takayanagi S, Ishikawa T. Multiple splicing variants of two new human ATP-binding cassette transporters, ABCC11 and ABCC12. Biochem Biophys Res Commun 2001;288:933-9.
35. Kool M, de Haas M, Scheffer GL, et al. Analysis of expression of cMOAT (MRP2), MRP3, MRP4, and MRP5, homologues of the multidrug resistance-associated protein gene (MRP1), in human cancer cell lines. Cancer Res 1997;57:3537-47.
36. Dazert PMK, Vogelgesang S, Heydrich B, et al. Expression and localization of the multidrug resistance protein 5 (MRP5/ABCC5), a cellular export pump for cyclic nucleotides, in human heart. Am J Pathol 2003; 163:1567-77.
37. Hurbain I, Sermet-Gaudelus I, Vallee B, et al. Evaluation of MRP1-5 gene expression in cystic fibrosis patients homozygous for the {Δ}F508 mutation. Pediatr Res 2003;54:627-34.
38. Gekeler V, Ise W, Sanders KH, Ulrich W-R, Beck J. The leukotriene LTD4 receptor antagonist MK571 specifically modulates MRP associated multidrug resistance. Biochem Biophys Res Commun 1995;208:345-52.
39. Jedlitschky G, Leier I, Buchholz U, et al. Transport of glutathione, glucuronate, and sulfate conjugates by the MRP gene-encoded conjugate export pump. Cancer Res 1996;56:988-94.
40. Gollapudi S, Kim CH, Tran B-N, Sangha S, Gupta S. Probenecid reverses multidrug resistance in multidrug resistance-associated protein-overexpressing HL60/AR and H69/AR cells but not in P-glycoprotein-overexpressing HL60/Tax and P388/ADR cells. Cancer Chemother Pharmacol 1997;40:150-8.
41. Bodo A, Bakos E, Szeri F, Varadi A, Sarkadi B. Differential modulation of the human liver conjugate transporters MRP2 and MRP3 by bile acids and organic anions. J Biol Chem 2003;278:23529-37.
42. Bakos E, Evers R, Sinko E, et al. Interactions of the human multidrug resistance proteins MRP1 and MRP2 with organic anions. Mol Pharmacol 2000;57:760-8.
43. Reid G, Wielinga P, Zelcer N, et al. Characterization of the transport of nucleoside analog drugs by the human multidrug resistance proteins MRP4 and MRP5. Mol Pharmacol 2003;63:1094-103.
44. Linsdell P, Hanrahan JW. Substrates of multidrug resistance-associated proteins block the cystic fibrosis transmembrane conductance regulator chloride channel. Br J Pharmacol 1999;126:1471-7.
45. Linsdell P, Hanrahan JW. Glutathione permeability of CFTR. Am J Physiol Cell Physiol 1998;44:C323-6.
46. Schultz BD, Singh AK, Devor DC, Bridges RJ. Pharmacology of CFTR chloride channel activity. Physiol Rev 1999;79:S109-44.
47. Ford JM, Hait WN. Pharmacology of drugs that alter multidrug resistance in cancer. Pharmacol Rev 1990;42:155-99.
48. Norman BH. Inhibitors of MRP1-mediated multidrug resistance. Drugs of the Future 1998;23:1001-13.
49. Dantzig AH, Law K, Cao J, Starling JJ. Reversal of multidrug resistance by the P-glycoprotein modulator, LY335979, from the bench to the clinic. Curr Med Chem 2001;8:39-50.
50. Lee C. Reversing agents for ATP-binding cassette (ABC) transporters: application in modulating multidrug resistance (MDR). Curr Med Chem 2004;4:43-52.
51. Sandusky G. Expression of MRP5 in normal human tissues and carcinomas using tissue microarrays. In: Proc Am Assoc Cancer Res; 2002 Apr 6-10; San Francisco, CA. Linthicum: Cadmus; 2002.